Drugs / IBI324
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05489718 | Aug 2022 → Jun 2023 | diabetic macular edema | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema innoventbio.com ↗
Final results released include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324. |
| 2026-03-30 | Ollin Biosciences, Inc. | Results Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema ollin.bio ↗
Final results released today include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs). |
| 2026-01-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration innoventbio.com ↗
OLN324 demonstrated both faster and greater retinal drying versus faricimab in patients with DME |
| 2026-01-08 | Ollin Biosciences, Inc. | Results Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration ollin.bio ↗
Nearly 90% of DME patients treated with OLN324 4mg achieved absence of disease at 12 weeks compared to 57% of patients treated with faricimab |
| 2025-09-17 | Ollin Biosciences, Inc. | Results Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology ollin.bio ↗
In a completed Phase 1 single and multiple dose escalation study conducted in DME patients in China, OLN324 demonstrated promising vision and anatomic improvements along with a favorable safety profile. |
| 2023-11-06 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023 innoventbio.com ↗
IBI302 and IBI324 have demonstrated positive efficacy and safety results in nAMD and DME, respectively. |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05489718 ↗ |
| Modality | Monoclonal antibody | “IBI324, a vascular endothelial growth factor-A/angiopoietin-2 bispecific antibody” PMID 41494748 ↗ Jan 2026 |
| Route | Intravitreal | “single intravitreal injection (IVT) of 0.5 mg, 2 mg or 4 mg IBI324” PMID 41494748 ↗ Jan 2026 |